167 related articles for article (PubMed ID: 17369583)
1. KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors.
De Giorgi U
J Clin Oncol; 2007 Mar; 25(9):1146-7; author reply 1147-8. PubMed ID: 17369583
[No Abstract] [Full Text] [Related]
2. Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.
Zheng S; Pan YL; Tao DY; Wang JL; Huang KE
Scand J Gastroenterol; 2009; 44(6):760-3. PubMed ID: 19096980
[TBL] [Abstract][Full Text] [Related]
3. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.
Haller F; Detken S; Schulten HJ; Happel N; Gunawan B; Kuhlgatz J; Füzesi L
Ann Surg Oncol; 2007 Feb; 14(2):526-32. PubMed ID: 17139461
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials.
Patel S; Zalcberg JR
Eur J Cancer; 2008 Mar; 44(4):501-9. PubMed ID: 18234488
[TBL] [Abstract][Full Text] [Related]
5. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR
Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352
[TBL] [Abstract][Full Text] [Related]
6. KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient.
Tamborini E; Gabanti E; Lagonigro MS; Negri T; Pilotti S; Pierotti MA; Pricl S
Cancer Res; 2005 Feb; 65(3):1115; author reply 1115. PubMed ID: 15705916
[No Abstract] [Full Text] [Related]
7. [A step foward in the treatment of GIST].
Fattoruso SI; Lopez M
Clin Ter; 2008; 159(4):223-4. PubMed ID: 18776977
[No Abstract] [Full Text] [Related]
8. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
Chen LL; Trent JC; Wu EF; Fuller GN; Ramdas L; Zhang W; Raymond AK; Prieto VG; Oyedeji CO; Hunt KK; Pollock RE; Feig BW; Hayes KJ; Choi H; Macapinlac HA; Hittelman W; Velasco MA; Patel S; Burgess MA; Benjamin RS; Frazier ML
Cancer Res; 2004 Sep; 64(17):5913-9. PubMed ID: 15342366
[TBL] [Abstract][Full Text] [Related]
9. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
[TBL] [Abstract][Full Text] [Related]
10. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
Negri T; Pavan GM; Virdis E; Greco A; Fermeglia M; Sandri M; Pricl S; Pierotti MA; Pilotti S; Tamborini E
J Natl Cancer Inst; 2009 Feb; 101(3):194-204. PubMed ID: 19176456
[TBL] [Abstract][Full Text] [Related]
11. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH
Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947
[TBL] [Abstract][Full Text] [Related]
12. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
[TBL] [Abstract][Full Text] [Related]
13. The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor.
Gronchi A; Blay JY; Trent JC
Cancer; 2010 Apr; 116(8):1847-58. PubMed ID: 20166214
[TBL] [Abstract][Full Text] [Related]
14. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Kim HC; Kim KH; Yook JH; Kim BS; Kang YK
J Surg Oncol; 2008 Jul; 98(1):27-33. PubMed ID: 18452195
[TBL] [Abstract][Full Text] [Related]
15. FDA updates Gleevec label for GIST patients.
Schmidt C
J Natl Cancer Inst; 2012 Mar; 104(5):346. PubMed ID: 22349200
[No Abstract] [Full Text] [Related]
16. Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate.
Sciot R; Debiec-Rychter M; Daugaard S; Fisher C; Collin F; van Glabbeke M; Verweij J; Blay JY; Hogendoorn PC; ; ;
Eur J Cancer; 2008 Sep; 44(13):1855-60. PubMed ID: 18653326
[TBL] [Abstract][Full Text] [Related]
17. Imatinib in advanced gastrointestinal stromal tumour: when is 800 mg the correct dose?
Judson I
Curr Opin Oncol; 2008 Jul; 20(4):433-7. PubMed ID: 18525340
[TBL] [Abstract][Full Text] [Related]
18. [A case of recurrent GIST successfully treated with low-dose imatinib mesilate].
Hanada N; Kawamura Y; Taneda T; Yoshida Y; Osako T; Inoue K
Gan To Kagaku Ryoho; 2006 Jun; 33(6):799-801. PubMed ID: 16770100
[TBL] [Abstract][Full Text] [Related]
19. Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones.
Loughrey MB; Beshay V; Dobrovic A; Zalcberg J; Waring PM
Histopathology; 2006 Jul; 49(1):99-100. PubMed ID: 16842259
[No Abstract] [Full Text] [Related]
20. [Effect of c-kit mutation on the prognosis of gastrointestinal stromal tumors: a meta-analysis].
Zhao WY; Cao H; Zhang Y; Shen ZY; Wu ZY
Zhonghua Wai Ke Za Zhi; 2009 Jun; 47(11):857-62. PubMed ID: 19961019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
